Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells

Clinical Cancer Research

Volumn 12, Issue 16, 2006, Pages 4989-4999

  Park, Ji Sun ^a   Jun, Hyun Jung ^a   Cho, Moon Jun ^b   Cho, Kwan Ho ^a   Lee, Jin Soo ^a   Zo III, Jae ^a   Pyo, Hongryull ^a  

^a National Cancer Center   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CELL LEVEL; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION RESPONSE; RADIOSENSITIVITY; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LUNG NEOPLASMS; PYRAZOLES; QUINAZOLINES; RABBITS; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES;

EID: 33748374700     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2259     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Dy GK, Adjei AA. Novel targets for lung cancer therapy. Part I. J Clin Oncol 2002;20:2881-94.
3. Dy GK, Adjei AA. Novel targets for lung cancer therapy. Part II. J Clin Oncol 2002;20:3016-28.
4. Baumann M, Krause M, Zips D, et al. Molecular targeting in radiotherapy of lung cancer. Lung Cancer 2004;45:S187-97.
5. Pao W, Miller VA. Epidermal growth factor receptor mutations, small molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
6. Anderson SM, Hayward WS, Neel BG, Hanafusa H. Avian erythroblastosis virus produces two mRNA's. J Virol 1980;36:676-83.
7. Vennstrom B, Bishop JM. Isolation and characterization of chicken DNA homologous to the two putative oncogenes of avian erythroblastosis virus. Cell 1982;28:135-43.
8. Yamamoto T, Hihara H, Nishida T, Kawai S, Toyoshima K. A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas. Cell 1983;34:225-32.
9. Salomon DS, Brandt R, Ciardiello F, Normanno N Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
10. Ochs JS. Rationale and clinical basis for combining gefitinib (Iressa, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 2004;58:941-9.
11. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 1991;60:281-319.
12. Williams CS, Mann M, Du Bois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
13. Pyo H, Du Bois RN, Choy H. The role of cyclooxygenase-2 inhibitors in combined modality therapy. In: Choy H, editor. Chemoradiation in cancer therapy. New Jersey: Humana Press; 2003. p. 391-408.
14. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66.
15. Shin YK, Park JS, Kim HS, et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005;65:9501-9.
16. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91.
17. Kano Y, Ohnuma T, Okano T, Holland JF. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 1988;48:351-6.
18. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604-10.
19. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141.
20. Kano Y, Akutsu M, Tsunoda S, Mori K, Suzuki K, Adachi K. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol 1998;42:91-8.
21. Lau CE, Wang Y, Falk JL. Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: independent interaction of alprazolam and caffeine. J Pharmacol Exp Ther 1997;281:1013-29.
22. Lau CE, Wang Y, Falk JL. Independent interaction of alprazolam and caffeine under chronic dose regimens on differential reinforcement of low-rate (DRL 45-s) performance. Psychopharmacology (Berl) 1997;134:277-86.
23. Faust M, Altenburger R, Backhaus T, et al. Joint algal toxicity of 16 dissimilarly acting chemicals is predictable by the concept of independent action. Aquat Toxicol 2003;63:43-63.
24. Simeone AM, Broemeling LD, Rosenblum J, Tari AM. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl) retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. Oncogene 2003;22:6739-47.
25. Chen Z, Zhang X, Li M, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:5930-9.
26. Tortora G, Caputo R, Damiano V, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003;9:1566-72.
27. Lam GK. Analysis of interaction for mixtures of agents using the linear isobole. Bull Math Biol 1989;51:293-309.
28. Herbst RS, Bunn PA, Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003;9:5813-24.
29. Sirotnak FM. Studies with ZD1839 in preclinical models. Semin Oncol 2003;30:12-20.
30. L858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64:7241-4.
31. 1-Cell cycle arrest and apoptosis in human adenocarcinoma A549 cells. Biochem Pharmacol 2004;68:1453-64.
32. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogeneic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004;67:1469-78.
33. kip1 and cell cycle arrest. Cancer Res 2004;64:1369-76.
34. Riedl K, Krysan K, Pold M, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 2004;7:169-84.
35. Lai GH, Zhang Z, Sirica AE. Celecoxib acts in a cyclooxygenase-2- independent manner and in syner-gy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspase-9 and -3. Mol Cancer Ther 2003;2:265-71.
36. Kulp SK, Yang YT, Hung CC, et al. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51.
37. Song X, Lin HP, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-91.
38. 2 checkpoint abrogators. Curr Med Chem Anti-Canc Agents 2003;3:35-46.
39. 2 DNA damage checkpoint and their potential for cancer therapy. Prog Cell Cycle Res 2003;5:423-30.
40. Wilson GD. Radiation and the cell cycle, revisited. Cancer Metastasis Rev 2004;23:209-25.